Related Experiment Video
Updated: Mar 21, 2026
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease: Propensity-Matched
Rishi Chowdhary1, Manjeet Kumar Goyal2, Ashita Rukmini Vuthaluru3
1Department of Medicine, MetroHealth Medical Center, Cleveland, Ohio, USA.
Background And Aims:
Lean metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized; however, its long-term hepatic risk relative to obese MASLD remains elusive. This study evaluated differential risk of progressive hepatic outcomes and identified predictors of adverse outcomes within the lean phenotype.
Methods:
A large, multicenter retrospective cohort study was conducted using the TriNetX Global Health Research Network, including adults with noncirrhotic MASLD between 2010 and 2024. Lean MASLD was defined as the body mass index (BMI) < 25 kg/m2. Primary analyses compared lean versus nonlean MASLD (BMI ≥ 25 kg/m2), with a prespecified secondary analysis comparing lean versus obese MASLD (BMI ≥ 30 kg/m2), excluding overweight individuals. Outcomes included incident fibrosis, cirrhosis, portal hypertension and related complications, hepatocellular carcinoma (HCC), liver transplantation, and all-cause mortality over 3-year, 5-year, and 10-year follow-up. Propensity score matching and multivariable Cox regression were applied.
Results:
Among 1,130,297 patients with MASLD, 229,084 had lean MASLD. After matching, lean MASLD was associated with consistently higher odds of fibrosis, cirrhosis, portal hypertensive complications, HCC, liver transplantation, and mortality compared with nonlean, overweight, and obese MASLD across all time horizons (all p < 0.001). Within the lean MASLD cohort, those with older age, diabetes, hypoalbuminemia, thrombocytopenia, and elevated aspartate aminotransferase independently predicted adverse hepatic outcomes.
Conclusions:
Lean MASLD is associated with substantial long-term hepatic morbidity and mortality. Currently, obesity-centered paradigms guide MASLD screening and risk stratification. Thus, efforts should be made to ensure that lean individuals with MASLD are not systematically under-screened or under-surveilled for progressive liver disease as they carry a higher risk of worsening.
More Related Videos
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion